Avalyn Pharma announced it will present two studies at the American Thoracic Society 2026 conference, focusing on patient experiences with its inhaled therapy AP01 and supportive care in pulmonary fibrosis. The presentations highlight Avalyn's commitment to incorporating patient and caregiver feedback to improve treatment usability and healthcare support. These findings support Avalyn's ongoing clinical trials of inhaled antifibrotic drugs aimed at improving lung function and reducing side effects in pulmonary fibrosis patients. The company aims to set a new standard of care with its inhaled therapies targeting rare respiratory diseases.
Hope Bancorp, Inc. reported Q2 2026 earnings per share of $0.27, surpassing the expected $0.26 and up from $0.19 last year, indicating improved profitability. The company also exceeded revenue forecasts with $147.82 million versus the estimated $146....
UDR, Inc. is set to report Q2 2026 earnings with analysts projecting $0.13 per share on $423.35 million revenue, reflecting a 1.6% year-over-year earnings decline. Despite this, UDR anticipates sequential growth in adjusted funds from operations (FFO...
Joe Cicero, Chief Marketing Officer at Security Risk Advisors, has been named a finalist in the 2026 CRN Best of the Channel Awards for Best Channel Visionary of the Year. He is recognized for unifying marketing, alliances, and sales into a partner-l...
Eneba, a fast-growing digital entertainment marketplace, has partnered with NetEase Games to become an official distributor of NetEase Pay gift cards worldwide. This allows users to buy gift cards in various USD denominations with instant delivery, r...
The Law Offices of Frank R. Cruz announced class action lawsuits against AeroVironment (AVAV), Calix (CALX), Zoetis (ZTS), and Lucid Group (LCID) for allegedly making false or misleading statements and withholding material adverse information about t...
